Abstract  Description  Claims  Drawing  Search report  Cited references 

US4673574A   [0033]  [0223] 
US4902506A   [0033]  [0223] 
US5614382A   [0035] 
WO2004083251A   [0036] 
WO9014837A   [0039] 
US4912094A   [0039] 
US5057540A   [0039] 
US6113918A   [0039] 
US6207646B   [0039] 
WO0018434A   [0039] 
WO02098368A   [0039] 
WO02098369A   [0039] 
WO9313302A   [0039] 
WO9219265A   [0039] 
US5601831A   [0048] 
WO03078453A   [0048] 
US5110908A   [0048] 
WO0100790A   [0048] 
US37741A   [0048] 
US6245337B   [0048] 
US6676948B   [0048] 
US5643725A   [0048] 
US6221365B   [0048] 
US5552146A   [0049] 
US6310190B   [0049] 
US5725862A   [0049] 
US5948412A   [0049] 
US6899885B   [0049] 
WO03048304A   [0050] 
WO02083855A   [0051] 
WO02053761A   [0051] 
WO03063766A   [0052] 
WO2004094596A   [0052] 
WO0185772A   [0052] 
WO0216612A   [0052] 
WO0187939A   [0052] 
US19951998B   [0223] 
US19781994B   [0223] 

Ped. Inf. Dis. J.   [0019] 
17th Annual Meeting of the Eur. Soc. Paed. Inf. Dis. (ESPID   [0019] 
J. Biol. Chem.   [0080] 
Which pneumococcal serogroups cause the most invasive disease: implications for conjugate vaccine formulation and use, part I   [0223] 
The contribution of specific pneumococcal serogroups to different disease manifestations: implications for conjugate vaccine formulation and use, part I.   [0223] 
Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine   [0223] 
Postlicensure evaluation of the effectiveness of seven valent pneumococcal conjugate vaccine   [0223] 
Opportunities for prevention in the conjugate vaccine era   [0223] 
J Infect Dis   [0223] 
Increasing prevalence of multidrug-resistant Streptococcus pneumoniae in the United States   [0223] 
The prevalence of drug-resistant Streptococcus pneumoniae in Atlanta   [0223] 
Pneumococcal conjugate vaccine serotypes of Streptococcus pneumoniae isolates and the antimicrobial susceptibility of such isolates in children with otitis media   [0223] 
Efficacy, safety, and immunogenicity of heptavalent pneumococcal conjugate vaccine in children   [0223] 
Serotype distribution and antimicrobial resistance pattenrs of invasive isolates of Streptococcus pneumoniae: Alaska, 1991-1998   [0223] 
Potential interventions for the prevention of childhood pneumonia: geographic and temporal differences in serotype and serogroup distribution of sterile site pneumococcal isolates from children: implications for vaccine strategies   [0223] 
The epidemiology of invasive pneumococcal disease in children in Far North Queensland   [0223] 
Invasive Streptococcus pneumoniae infection in Latin American children: results of the Pan American Health Organization Surveillance Study   [0223] 
Geographical differences in invasive pneumococcal disease rates and serotype frequency in young children   [0223] 
Incidence and etiologies of complicated parapneumonic effusions in children, 1996 to 2001   [0223] 
An epidemiological investigation of a sustained high rate of pediatric parapneumonic empyema: risk factors and microbiological associations   [0223] 
Clinical characteristics with complicated pneumonia caused by Streptococcus pneumoniae.   [0223] 
Pneumococcal serotypes from acute otitis media in rural Kentucky   [0223] 
Multinational study of pneumococcal serotypes causing acute otitis media in children   [0223] 
Considerations for formulating the second-generation pneumococcal capsular polysaccharide vaccine with emphasis on the cross-reactive types within groups   [0223] 
Identification of cross-reactive antibodies with low opsonophagocytic activity for Streptococcus pneumoniae   [0223] 
Immunity to cross-reactive serotypes induced by pneumococcal conjugate vaccines in infants   [0223] 
Cross-reactivity of antibodies to type 6B and 6A polysaccharides of Streptococcus pneumoniae, evoked by pneumococcal conjugate vaccines, in infants   [0223] 
Immune response to cross-reacting pneumococcal serotypes 6A/6B and 19A/19F in the FinOM vaccine trial   [0223] 
Antibody responses in adult volunteers to pneumococcal polysaccharide types 19F and 19A administered singly and in combination   [0223] 
Immunogenicity and efficacy of Streptococcus pneumoniae polysaccharide-protein conjugate vaccines against homologous and heterologous serotypes in the chinchilla otitis media model   [0223] 
Serum samples from infants vaccinated with a pneumococcal conjugate vaccine, PncT, protect mice against invasive infection caused by Streptococcus pneumoniae serotypes 6A and 6B   [0223] 
Pneumococcal serotype 19F conjugate vaccine induces cross-protective immunity in serotype 19A in a murine pneumococcal pneumonia model   [0223] 
A trial of a 9-valent pneumococcal conjugate vaccine in children with and those without HIV infection   [0223] 
Efficacy and safety of seven-valent conjugate pneumococcal vaccine in American Indian children: group randomised trial   [0223] 
Efficacy of a pneumococcal conjugate vaccine against acute otitis media   [0223] 
Effectiveness of heptavalent pneumococcal conjugate vaccine in children. Abst G-1079   [0223]